COGNITIVE AND DEPRESSIVE DISORDERS IN MULTIPLE SCLEROSIS
|
|
|
- Earl Jacobs
- 10 years ago
- Views:
Transcription
1 A. Acta Alajbegoviæ Clin Croat et al. 2009; 48:3-8 Cognitive and depressive disorders Original in multiple Scientific sclerosis Paper COGNITIVE AND DEPRESSIVE DISORDERS IN MULTIPLE SCLEROSIS Azra Alajbegoviæ 1, Nataša Loga 1, Naida Tiro 2, Salem Alajbegoviæ 3, Veselin Cindro 4 and Izet Hozo 5 1 University Department of Neurology, Sarajevo University Clinical Center; 2 Institute of Occupational Medicine, Sarajevo Canton, Sarajevo; 3 Zenica Cantonal Hospital, Zenica, Bosnia and Herzegovina; 4 University Department of Neurology; 5 University Department of Medicine, Split University Hospital Center, Split, Croatia SUMMARY Among other symptoms, multiple sclerosis can also produce symptoms of affective and cognitive disorders. The majority of patients have certain cognitive dysfunctions, and the most common affective disorder is reactive depression. The aim of the study was to determine the correlation of the Mini-Mental State (MMS) and Beck Depression Inventory (BDI) scale scores with the Expanded Disability Status Scale (EDSS) score in patients with multiple sclerosis treated at University Department of Neurology, Sarajevo University Clinical Center in Sarajevo. We evaluated 50 randomly selected patients with various types of multiple sclerosis using the MMS, BDI and EDSS instruments. The study included 33 women and 17 men (66% : 34%), mean age years (SD 9.236). The mean value of EDSS score was 3.98, ranging from 1.0 to 8.5 in women and from 1.0 to 6.5 in men. BDI scale scores showed a mean value of The mean MMS score in baseline sample was Statistically significant positive correlation was found between age and EDSS score, and negative correlation between EDSS and MMS, as well as between BDI and MMS. Study results indicated older patients with multiple sclerosis to have a higher EDSS score with more pronounced cognitive disturbances. There was no statistically significant correlation between EDSS score and depression. Key words: Multiple sclerosis, psychology; Depressive disorders diagnosis; Cognitive disorders diagnosis; Disability evaluation Introduction Correspondence to: Azra Alajbegoviæ, MD, University Department of Neurology, Sarajevo University Clinical Center, Bolnièka 25, Sarajevo, Bosnia and Herzegovina [email protected] Received September 15, 2008, accepted in revised form February 17, 2009 Multiple sclerosis (MS) is a chronic inflammatory, noncontiguous, progressive, multifocal demyelinating and autoimmune disease of the central nervous system (white brain mass and spinal cord; CNS), which can manifest with various neurologic signs. MS can also produce symptoms of affective and cognitive disorders. Cognitive dysfunctions, which are usually irreversible, affect 40%-60% of patients 1. The most common cognitive dysfunctions are those involving attention, memory, speed of information processing, visual spatial perception and learning. These dysfunctions are closely related to the number and location of CNS lesions 2. In January 2002, the New York City Chapter of the National Multiple Sclerosis Society convened a panel of experts to review the issue of depressive affective disorders associated with MS. This Goldman Consensus Conference Study Group provides recommendations for improvement of diagnosis, screening, and clinical management for depressive disorders among patients suffering from MS. The prevalence of depressive disorders is between 27% and 75%, and according to Fisher et al., it is present in 47% to 54% of MS patients 3,4. Reactive depression is the most common affective disorder 5. Depression and cognitive dysfunctions in MS patients have negative impact on their working ability, social relationships and quality of life. The aim of this study was to determine the correlation of the Mini-Mental State (MMS) and Beck De- Acta Clin Croat, Vol. 48, No. 1, Alajbegovic.p65 3
2 pression Inventory (BDI) scale scores with the score of Expanded Disability Status Scale (EDSS) in MS patients treated at University Department of Neurology, Sarajevo University Clinical Center in Sarajevo. Material and Methods We evaluated 50 randomly selected patients with various types of MS. All patients had Poser criteria for definitive diagnostic categories of MS: consistent course (relapsing/remitting) with at least 2 bouts by at least 1 month apart; or slow, stepwise progressive course for at least 6 months, documented neurologic signs of lesions in more than one area (functional system) of the brain or spinal cord white matter, onset of symptoms at age between 10 and 50 years, and absence of another more likely neurologic explanation 6,7. MMS is a current screening test used to evaluate a wide spectrum of cognitive functions. It contains 30 short questions, and each positive answer carries 1 point. A total score between 28 and 30 points is considered as normal, between 24 and 28 indicates mild cognitive impairment, and a score below 24 indicates diffuse cognitive impairments and requires additional diagnostic evaluation. BDI contains 21 category attitudes related to depression and each one is assessed by the four-grade severity scale. A BDI score between 1 and 10 is interpreted as normal mood, between 11 and 16 as mild mood disorder, 17 to 20 as borderline depression, 21 to 30 as mild depression, 31 to 40 as severe depression, and a score above 40 as extremely pronounced depression. EDSS is a unified scale for the assessment of functioning in MS patients, which includes exploration of impairment in several functional systems. Total score on EDSS scale can be between 0.0 (normal neurologic status) to up to 10.0 (lethal outcome due to MS). Selected patients were clinically followed at the outpatient department for demyelinating disorders of the University Department of Neurology. The instruments used in the study were MMS, BDI and EDSS. Statistical significance of differences was determined by use of Student s t-test and correlation between study variables by Spearman correlation coefficient with the level of significance set at P<0.05. Results The study included 50 patients, 33 women and 17 men (66%: 34%), mean age years (SD 9.236). 66% Fig. 1. Sex distribution of patients with multiple sclerosis. There was a statistically significant sex difference in favor of female patients (P=0.0257), but there was no statistically significant age difference (t=0.0042; P=0.756) (Figs. 1 and 2). Fig. 2. Patient distribution according to sex and age groups. The mean value of EDSS score was 3.98, with variations from 1.0 to 8.5 among women and from 1.0 to 6.5 among men. According to this, an average patient was fully mobile without any assistance, independent for more than 12 hours per day and able to walk without assistance or rest for approximately 500 meters. Statistical analysis by Student s t-test indicated that there was no significant sex difference in EDSS score (t= ; P=0.876) (Fig. 3). Fig. 3. Mean values of EDSS score. 34% 4 Acta Clin Croat, Vol. 48, No. 1, Alajbegovic.p65 4
3 Fig. 4. Mean values of BDI scale score. BDI scale yielded a mean score of The mean BDI score showed some sex differences with slightly higher values in male patients, however, the difference did not reach statistical significance (t=0.0526; P=0.286) (Fig. 4). Fig. 7. Correlation between EDSS and MMS. rho=-0.186; P=0.156). BDI scale score yielded positive correlation with patient age (Spearman rho=0.653; P=0.0487). Correlation analysis of age and MMS score indicated that age had almost no influence on MMS score (Spearman rho=0.0084; P=0.726) (Fig. 6). We also correlated EDSS with MMS and BDI with MMS. Both correlations yielded negative, statistically significant correlation coefficients (EDSS to MMS: rho=-0.725; P=0.0026; and BDI to MMS: rho=-0.589; P=0.0429) (Figs. 7 and 8). Fig. 5. Mean values of MMS scale score. In our sample, the mean MMS score was 26.88, with nearly identical values in male and female patients: ( and , respectively). According to this, Student s t-test indicated that there was no significant between-group difference (t= ; P=0.982 (Fig. 5). We correlated EDSS, BDI, MMS and age by use of Spearman matrix. EDSS score showed negative, statistically non-significant correlation with age (Spearman Fig. 6. Correlation between EDSS, BDI, MMS scores and age. Fig. 8. Correlation between BDI and MMS. Discussion This study raised a question of relation between neurologic impairment in MS and mental disorders, among which this study was focused on the symptoms of cognitive and emotional deficits. Our study included 33 women and 17 men (66%:34%), mean age years (SD 9.236), which is comparable to the study reported by Birnboim and Miller, who had 60% of female and 40% of male patients, mean age years (SD 8.09) 8. It is well known that cognitive dysfunction is a major cause of disability in patients with MS and it profoundly undermines the patient s quality of life 9. Cognitive disorders are present in 13%-72% of patients with MS, and can be found in 43%-46% of cases on an average, rarely in the early stage of disease. MS involves Acta Clin Croat, Vol. 48, No. 1, Alajbegovic.p65 5
4 specific cognitive problems in the domain of attention, memory (short-term and long term), speed of information processing, abstract thinking, visuospatial perception and learning. Cognitive deficit does not correlate with physical disability, fatigue or depression, but there is a significant connection with cortical or subcortical lesion recorded on MRI. Cognition impairment need not be irreversible, often relapsing disease, and glucocorticoid therapy may lead to transient deterioration. MMS is a modern screening test for assessing the wide spectrum of cognitive functions. It contains 30 short questions and each accurate answer is 1 point. A total score of 28 to 30 points is considered to be normal, indicates mild cognitive impairment, and score below 24 indicates diffuse cognitive damage and requires additional testing. The mean MMS score in a baseline sample was 26.88, which means that the average patient had mild cognitive problems and the variations in MMS score ranged from normal results to diffuse cognitive dysfunction. There was no statistically significant sex difference in terms of cognitive problems. We used MMS, but in our future studies we will have to use the Perceived Deficits Questionnaire of Multiple Sclerosis Quality of Life Inventory (PDQ), which accurately measures selfreported symptoms of psychological impairment 10. Depression is the most common disorder that can be found in 27%-75% of MS patients, followed by euphoria in 25%, mainly in patients with progressed brain atrophy and with sparse cognitive and neurologic finding. BDI is a measure for the general depressive symptoms, which contains 21 categories of attitudes, and each is estimated on four-grade scale representing the degree of disturbance severity. A BDI score 1-10 is considered as normal mood, as mild mood disorder, indicates borderline clinical depression, moderate depression, severe depression, and score over 40 is extremely pronounced depression. Our patients had a mean BDI score of 12.56, which indicates the existence of mild depression symptoms, without statistically significant sex differences. The Goldman Group expressed general agreement that some sort of scalebased assessment of depression in MS population would be helpful in screening of these depressive disorders. Our results of the mean BDI score were within the current gold standard for the diagnosis of depressive disorders in MS population (Goldman Consensus Group) 11. EDSS is a unified scale for assessing disability in MS patients, which includes exploration of impairments in multiple functional systems. The total score on the EDSS scale ranges from 0.0 (normal neurologic status) to up to 10.0 (death due to MS). EDSS as an indicator of the extent of disablement showed a wide range, with a mean value of 3.98 and mean age 40.74, which explains the negative statistical correlation between MMS, BDI, MMS and EDSS in our material, with a remark that the goal of the study was to determine depressive and affective disorders in our sample of 100 patients, thus to provide projections for our future approach in the management of these patients with medication, psychotherapy and sociotherapy, tending to complete the multimodal approach to this category of patients. Our results of EDSS with a mean EDSS of 3.98 in our patients are comparable to those reported by Werf et al. in and by Birnboim and Miller with EDSS of In our study, there was no statistically significant correlation between EDSS and BDI. This could be explained by the significant cognitive dysfunction in patients with higher EDSS score. We found a statistically significant positive correlation between age and EDSS score, whereas negative correlation was recorded between EDSS and MMS, and between BDI and MMS. Our results of negative correlation between EDSS and BDI are consistent with the results reported by Moller et al., according to which the presence of depressive symptomatology did not correlate with the severity of neurologic disability 13. The results of the present study explicitly indicated that mental disorders should be considered and psychiatric therapy administered during the treatment of MS, which is often neglected 14. In 2008, Siepman et al. reported the results of their study designed as a study of mutual correlation of the level of disablement, depression and cognitive impairments in 101 patients with MS. They found that cognitive dysfunction was significantly more present among patients with depressive disorders in comparison to those free from depression on the depression scale, and that the level of disablement could progress in the very early stage after detection of the disease (in two years) 15. Cognitive impairment in patients with MS further complicates diagnostic evaluation 16. In our patient sample, Spearman test identified a statistically significant positive correlation between age and EDSS score (rho=0.287; P<0.05) and negative correlation between EDSS and MMS (rho=-0.442; P<0.01) as well as between BDI and MMS (rho= 0.382; P<0.01). In January 2009, Christodoulou et al. published the results of a longitudinal study performed in 38 patients with MS 6 Acta Clin Croat, Vol. 48, No. 1, Alajbegovic.p65 6
5 and found that negative affect could be a predictor of cognitive impairment, especially in the area of vertebral and visuospatial functioning 17. The etiology of depression in these patients is not well understood and has been varyingly attributed to emotional reaction to the diagnosis or disability associated with the neurologic condition, the anatomical and/ or neurochemical outcomes of neurodegeneration, and the influence of other disease factors. Beyond the inherent burden depression places upon patients and caregivers, it increases cognitive and functional disability and, depending on MS, poorer treatment adherence and recovery, earlier institutionalization, and an increased risk of suicidal behavior 16. Little is known about the perception of body image in women diagnosed with relapsing remitting MS (RRMS). There are some studies of correlation between body image and depression in women diagnosed with RRMS. Kindrat reports that there are important psychological aspects which clinicians might need to attend when working with women with RRMS 18. Because of the high prevalence and implications for the quality of life and possibly disease progression, depression has been studied in MS. Yet, publications of theoretical work attempting to explain depression in a comprehensive way are scarce 19. Our results of the moderately present depressive affect in our sample are comparable to the results reported by Beiske et al., demonstrating a significant statistical correlation between depression and MS, with a note that these authors found a relatively high score of anxiety of 19.3% among younger patients 20. A number of studies suggest that depression in MS patients responds to antidepressant medication and occasionally to psychotherapeutic approaches 18. Conclusions Results of this study indicated that older patients with MS had a higher EDSS score with more pronounced cognitive disturbances. We found no statistically significant correlation between physical impairment and depression. Both cognitive and depressive disorders were equally present in both sexes. Cognitive dysfunctions were more pronounced in later stage of the disease. The frequency and severity of depressive symptoms did not correlate with physical impairment. Prompt detection and treatment (both neurologic and psychiatric) of cognitive and affective mental functions improve rehabilitation and quality of life in patients with multiple sclerosis. References 1. FIGVED N, KLEVAN G, MYHR KM, NYLAND H, LARSEN JP, OMAD R, AARSLAND D. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatr Scand 2005; 112: ALAJBEGOVIÆ-KURTOVIÆ A. Multipla skleroza. MS thesis. Sarajevo: University of Sarajevo, FISHER JS, FOLEY FW, AIHENS JE, ERICSON GD, RAO SM. What do we really know about cognitive dysfunction, affective disorders and stress in multiple sclerosis? A prac titioner s guide. J Neurol Rehab 1994;8: ARNETT PA, RANDOLPH JJ. Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006;77: PATTEN SB, BECK CA, WILLIAMS VA, BARLUI C, METZ LM. Major depression in multiple sclerosis. Am Acad Neurol 2003;61: POSER CM, PETY DW, McDONALD W, SCHEINBERG L, EBERS CG. New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann Neurol 1983;13: MURRAY TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006;332: BIRNBOIM S, MILLER A. Cognitive strategies application of multiple sclerosis patients. Multiple Sclerosis 2004;10: BARGET B. Cognitive dysfunction in MS. CNS Drugs 2002: 26: LOVERA J, BAGERT B, SMOOT KH, WILD K, FRANK R, BOGARDUS K, OKEN BS, WHITHAM RH, BOURDETTE DN. Correlations of Perceived Deficits Questionnaire of Multiple Sclerosis Quality of Life Inventory with Beck Depression Inventory and neuropsychological test. J Rehabil Res Dev 2006; 43: The Goldman Consensus statement on depression in multiple sclerosis. Multiple Sclerosis 2005;11: Van der WERF SP, JONGEN PJ, LYCKLAMA a NIJEHOLT G, BARKOF F, HOMMES OR, BLEIJENBERG G. Fatigue in multiple sclerosis between fatigue complaints, cerebral MRI abnormalities and neurological disability. J Neurol Sci 1998;160: MOLLER A, WIEDEMMAN G, ROHDE U, BACKMUND H, SONNTAG A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 1994;89: GALEAZZI GM, FERRARI S, GIAZOLI G, MACKIMON A, MERRELLI E, MATTI L, RIGATELLI M. Psychiatric disorders and depression in multiple sclerosis output patients: impact of disability and interferon beta therapy. J Neurol Sci 2005;26: SIEPMAN TA, JANSSENS AC, de KONING I, POLMAN CH, BORINGA JB, HINTZEN RQJ. The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis. J Neurol 2008;256: Epub 2008 May 20. Acta Clin Croat, Vol. 48, No. 1, Alajbegovic.p65 7
6 16. RASKIND MA. Diagnosis and treatment of depression comorbid with neurological disorders. Am J Med 2008;121(11 Suppl 2):S CHRISTODOULOU C, MELVILLE P, SCHERI WF, MACALLISTER WS, ABENSUR RL, TROXELL RM, KRUPP LB. Negative affect predicts subsequent cognitive change in multiple sclerosis. Int Neuropsychol Soc 2009;15: KINDRAT S. The relationship between body image and depression in women diagnosed with relapsing remitting multiple sclerosis. Can J Nurosci Nurs 2007;29: ARNETT PA, BARWICK PH, BEENEY JE. Depresssion in multiple sclerosis: review and theroetical proposal. Int Neuropsychol Soc 2008;14: BEISKE AG, SVENSSON E, SANDANGER I, CZUJKO B, PEDERSEN ED, AARSETH JH, MYHR KM. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol 2008; 15: Epub 2008 Jan 22 Sažetak SPOZNAJNI I DEPRESIVNI POREMEÆAJI KOD MULTIPLE SKLEROZE A. Alajbegoviæ, N. Loga, N. Tiro, S. Alajbegoviæ, V. Cindro i I. Hozo Meðu drugim simptomima multipla skleroza može uzrokovati i simptome afektivnih i spoznajnih poremeæaja. Veæina bolesnika ima odreðene spoznajne disfunkcije, dok je najèešæi afektivni poremeæaj reaktivna depresija. Cilj studije bio je utvrditi korelaciju vrijednosti dobivenih pomoæu ljestvica Mini-Mental State (MMS) i Beck Depression Inventory (BDI) s vrijednosti na ljestvici Expanded Disability Status Scale (EDSS) u bolesnika s multiplom sklerozom lijeèenih na Neurološkoj klinici Klinièkog bolnièkog centra u Sarajevu. Procjena je obuhvatila 50 nasumce izabranih bolesnika s razlièitim tipovima multiple skleroze uz primjenu MMS, BDI i EDSS. Bilo je 33 žena i 17 muškaraca (66%:34%) srednje dobi od 40,74 (SD 9,236) godine. Srednja vrijednost EDSS bila je 3,98, u rasponu od 1,0 do 8,5 kod žena te od 1,0 do 6,5 kod muškaraca. Na ljestvici BDI srednja vrijednost je bila 12,56, dok je srednja vrijednost za MMS u ispitanom uzorku bila 26,88. Utvrðena je statistièki znaèajna pozitivna korelacija izmeðu dobi i vrijednosti EDSS, dok je negativna korelacija utvrðena izmeðu EDSS i MMS te izmeðu BDI i MMS. Rezultati ovoga ispitivanja pokazali su da stariji bolesnici s multiplom sklerozom imaju višu vrijednost EDSS uz jaèe izražene kognitivne smetnje. Nije bilo statistièki znaèajne korelacije izmeðu vrijednosti EDSS i depresije. Kljuène rijeèi: Multipla skleroza, psihologija; Depresivni poremeæaji dijagnostika; Spoznajni poremeæaji dijagnostika; Invalidnost procjena 8 Acta Clin Croat, Vol. 48, No. 1, Alajbegovic.p65 8
Personality traits in multiple sclerosis: association with mood and anxiety disorders in a Romanian patients sample
Human & Veterinary Medicine International Journal of the Bioflux Society OPEN ACCESS Research Article Personality traits in multiple sclerosis: association with mood and anxiety disorders in a Romanian
Correlation between Expanded Disability Status Scale, Depression, Quality of Life and Age in Patients with Multiple Sclerosis
Standard Research Journal of Medicine and Medical Sciences Vol 3(1): 010-015, January 2015 (ISSN: 2409-0638) http://www.standresjournals.org/journals/srjmms Research Article Correlation between Expanded
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based
Clinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of
Relapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
Depression & Multiple Sclerosis
Depression & Multiple Sclerosis Managing specific issues Aaron, diagnosed in 1995. The words depressed and depression are used so casually in everyday conversation that their meaning has become murky.
Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest
Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest Cycle C June 2, 2015 1 Introduction The landscape for the treatment of relapsing Multiple Sclerosis (MS) has quickly evolved over
PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15
PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man
Depression & Multiple Sclerosis. Managing Specific Issues
Depression & Multiple Sclerosis Managing Specific Issues Feeling blue The words depressed and depression are used so casually in everyday conversation that their meaning has become murky. True depression
International Journal of Economics, Commerce and Management United Kingdom Vol. II, Issue 2, 2014
International Journal of Economics, Commerce and Management United Kingdom Vol. II, Issue 2, 2014 http://ijecm.co.uk/ ISSN 2348 0386 HEALTHCARE MANAGEMENT AND PSYCHOLOGICAL WELL-BEING IN PATIENTS WITH
OHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
Habib Hadianfard MD, 2 Nahid Ashjazadeh MD, 1 Soodabe Feridoni BS, 1 Elham Farjam BS
Neurology Asia 2015; 20(3) : 263 268 The role of psychological resilience, severity of disease and treatment adherence in the prediction of health-related quality of life in patients with multiple sclerosis
CNS Vital Signs Advancing Multiple Sclerosis Care
CNS Vital Signs Advancing Multiple Sclerosis Care Adding Value to Your Practice by Providing Solutions for Measuring, Monitoring and www.cnsvs.com Contents Why CNS Vital Signs?... Why CNS Vital Signs in
Accuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company.
Accuracy in Space and Time: Diagnosing Multiple Sclerosis 2012 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by www.msatrium.com, MS.US.PO876.1012 your gateway to MS knowledge.
PSYCHOLOGICAL AND NEUROPSYCHOLOGICAL TESTING
Status Active Medical and Behavioral Health Policy Section: Behavioral Health Policy Number: X-45 Effective Date: 01/22/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015
Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015 Introduction Wellness and the strategies needed to achieve it is a high priority
Fatigue in MS: 2005 update B. Colombo University of Milan - HSR
Fatigue in MS: 2005 update B. Colombo University of Milan - HSR Fatigue in MS One of the more disabling symptoms Affects about 75/90 % of the patients May be the onset symptom Transient or chronic May
MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION
MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION Michael K. Racke, MD Professor and Chairman in Neurology The Helen C. Kurtz Chair in Neurology Department of Neurology Ohio State University
Deirdre Dlugonski East Carolina University 160 Minges Coliseum 252.328.5266 [email protected]
Deirdre Dlugonski East Carolina University 160 Minges Coliseum 252.328.5266 [email protected] Education PhD University of Illinois, Kinesiology, 2013 BS Pennsylvania State University, Kinesiology, 2005
1695 N.W. 9th Avenue, Suite 3302H Miami, FL. 33136. Days and Hours: Monday Friday 8:30a.m. 6:00p.m. (305) 355 9028 (JMH, Downtown)
UNIVERSITY OF MIAMI, LEONARD M. MILLER SCHOOL OF MEDICINE CLINICAL NEUROPSYCHOLOGY UHEALTH PSYCHIATRY AT MENTAL HEALTH HOSPITAL CENTER 1695 N.W. 9th Avenue, Suite 3302H Miami, FL. 33136 Days and Hours:
New perception of disability including cognition, fatigue, pain and other impairments related to MS
New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for
ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
Clinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder
Clinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder AACAP Official Action: OUTLINE OF PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN, ADOLESCENTS, AND ADULTS WITH ADHD
Disability identity predicts lower anxiety and depression in multiple sclerosis
Disability identity predicts lower anxiety and depression in multiple sclerosis Bogart, K. R. (2015). Disability Identity Predicts Lower Anxiety and Depression in Multiple Sclerosis. Rehabilitation Psychology,
Cognitive Rehabilitation for Executive Dysfunction in Parkinson s Disease
Calleo, J., Burrows, C., Levin, H., Marsh, L., Lai, E., York, M. (2012). Cognitive rehabilitation for executive dysfunction in Parkinson s disease: application and current directions., vol. 2012, Article
DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
AUTISM SPECTRUM DISORDERS
AUTISM SPECTRUM DISORDERS JAGWINDER SANDHU, MD CHILD, ADOLESCENT AND ADULT PSYCHIATRIST 194 N HARRISON STREET PRINCETON, NJ 08540 PH: 609 751 6607 Staff Psychiatrist Carrier clinic Belle Mead NJ What is
Dr. Anna M. Acee, EdD, ANP-BC, PMHNP-BC Long Island University, Heilbrunn School of Nursing
Dr. Anna M. Acee, EdD, ANP-BC, PMHNP-BC Long Island University, Heilbrunn School of Nursing Overview Depression is significantly higher among elderly adults receiving home healthcare, particularly among
Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role
Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role What Is This Guide? This guide was compiled by the National Multiple Sclerosis Society as an aid to health care professionals
Tinnitus: a brief overview
: a brief overview sufferers experience sound in the absence of an external source. Sounds heard in tinnitus tend to be buzzing, hissing or ringing rather than fully-formed sounds such as speech or music.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
Clinical features. Chapter 2. Clinical manifestations. Course
Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent
Disease Modifying Therapies (DMTs) in Multiple Sclerosis
Disease Modifying Therapies (DMTs) in Multiple Sclerosis Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology Conflict of Interest Dr. Stobbe has no conflicts of
See also www.thiswayup.org.au/clinic for an online treatment course.
Depression What is depression? Depression is one of the common human emotional states. It is common to experience feelings of sadness and tiredness in response to life events, such as losses or disappointments.
Chapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015
Chemobrain Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Terminology Chemotherapy-associated cognitive dysfunction Post-chemotherapy cognitive impairment Cancer treatment-associated cognitive
Donna Graves, M.D. Assistant Professor University of Texas Southwestern Multiple Sclerosis Clinic
Donna Graves, M.D. Assistant Professor University of Texas Southwestern Multiple Sclerosis Clinic I have received honoraria from Teva pharmaceuticals, Novartis, and Bayer pharmaceuticals. Obtaining CME
Stage A & C Sample Data Collection Form
Stage A & C Sample Data Collection Form Instructions: Review a minimum of 20 patient charts (or another number determined to be appropriate) from patients most recently admitted, and complete this Data
How To Use A Drug In Multiple Sclerosis
Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and
06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity
PSYC PSYCHOLOGY. 2011-2012 Calendar Proof
PSYC PSYCHOLOGY PSYC1003 is a prerequisite for PSYC1004 and PSYC1004 is a prerequisite for all remaining Psychology courses. Note: See beginning of Section F for abbreviations, course numbers and coding.
LONG TERM HYPERBARIC OXYGENATION (HBO) RETARDS PROGRESSION IN MULTIPLE SCLEROSIS PATIENTS
LONG TERM HYPERBARIC OXYGENATION (HBO) RETARDS PROGRESSION IN MULTIPLE SCLEROSIS PATIENTS Abstract: Analysis of703 MS patients showed that 300 HBO treatments (about one treatment a fortnight over 10-13
AUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
VIRTUAL UNIVERSITY OF PAKISTAN FORMAT OF THE INTERNSHIP REPORT FOR BS Psychology (Clinical Setting)
VIRTUAL UNIVERSITY OF PAKISTAN FORMAT OF THE INTERNSHIP REPORT FOR BS Psychology (Clinical Setting) 1. Title page The title page of the report will include: Clinical Case Studies The name of the internee,
Global Economic Impact of Multiple Sclerosis
Global Economic Impact of Multiple Sclerosis May 2010 Literature Review Executive Summary Prepared for Multiple Sclerosis International Federation London, United Kingdom Prepared by Michael Trisolini,
Multiple Sclerosis: New Perspectives on the Patient Journey
Multiple Sclerosis: New Perspectives on the Patient Journey Prepared by Milliman, Inc., NY Bruce Pyenson, FSA, MAAA Principal and Consulting Actuary Melissa Fredericks, FSA, MAAA Principal and Consulting
Depression and its Treatment in Older Adults. Gregory A. Hinrichsen, Ph.D. Geropsychologist New York City
Depression and its Treatment in Older Adults Gregory A. Hinrichsen, Ph.D. Geropsychologist New York City What is Depression? Everyday use of the word Clinically significant depressive symptoms : more severe,
2.1 Who first described NMO?
History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first
Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
Mellen Center Approaches: Identifying and managing cognitive disorders in MS
Mellen Center Approaches: Identifying and managing cognitive disorders in MS Framework: Cognitive dysfunction is common in the MS population. It affects quality of life and correlates with worsened disease
THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine
THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine Volume 1, Issue 1 August 2007 The Depression Research Clinic at Stanford University
How To Cover Occupational Therapy
Guidelines for Medical Necessity Determination for Occupational Therapy These Guidelines for Medical Necessity Determination (Guidelines) identify the clinical information MassHealth needs to determine
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
Multiple sclerosis (MS) has been found to
Correlation of Physical Activity with Perceived Cognitive Deficits in Relapsing-Remitting Multiple Sclerosis Ruchika Shaurya Prakash, PhD; Erin M. Snook, PhD; Arthur F. Kramer, PhD; Robert W. Motl, PhD
Reversibility of Acute Demyelinating Lesions in relapsingremitting
Reversibility of Acute Demyelinating Lesions in relapsingremitting Multiple Sclerosis Omar A. Khan ( Division of Neuroimmunology, Department of Neurology, Neurology and Research Services. Veterans Affairs
Mental Health Needs Assessment Personality Disorder Prevalence and models of care
Mental Health Needs Assessment Personality Disorder Prevalence and models of care Introduction and definitions Personality disorders are a complex group of conditions identified through how an individual
SECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
IBADAN STUDY OF AGEING (ISA): RATIONALE AND METHODS. Oye Gureje Professor of Psychiatry University of Ibadan Nigeria
IBADAN STUDY OF AGEING (ISA): RATIONALE AND METHODS Oye Gureje Professor of Psychiatry University of Ibadan Nigeria Introduction The Ibadan Study of Ageing consists of two components: Baseline cross sectional
Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria
Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria AUTHORS Juan Luis Ruiz-Peña, Pablo Duque, and Guillermo Izquierdo Address: Unidad
A blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
Mental health problems in people with MS: What can we do? Eli Silber Consultant Neurologist Kings College hospital
Mental health problems in people with MS: What can we do? Eli Silber Consultant Neurologist Kings College hospital The emotional consequences of MS MS Population General Population Depression (Lifetime
Multiple Sclerosis: What You Need To Know. For Professionals
Multiple Sclerosis: What You Need To Know For Professionals What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society What MS Is: MS is thought
SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D]
SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D] I. Definitions: Detoxification is the process of interrupting the momentum of compulsive drug and/or alcohol use in an individual
EMOTIONAL AND BEHAVIOURAL CONSEQUENCES OF HEAD INJURY
Traumatic brain injury EMOTIONAL AND BEHAVIOURAL CONSEQUENCES OF HEAD INJURY Traumatic brain injury (TBI) is a common neurological condition that can have significant emotional and cognitive consequences.
Mellen Center for Multiple Sclerosis
Mellen Center Cleveland Clinic Marie Namey, RN, MSN, MSCN Mellen Center Cleveland Clinic Cleveland, OH Home of. Mellen Center for Multiple Sclerosis Mellen Center Mission The Mellen Center remains committed
MULTIPLE SCLEROSIS AND DEPRESSION. Michael Racke, MD The Ohio State University Meera Narasimhan, MD University of South Carolina
MULTIPLE SCLEROSIS AND DEPRESSION Michael Racke, MD The Ohio State University Meera Narasimhan, MD University of South Carolina MICHAEL RACKE, MD Disclosures!! Research/Grants: National Institute of Neurologic
The Role of Neuropsychology in the Treatment of MS
The Role of Neuropsychology in the Treatment of MS Jeffrey Wilken, Ph.D. Director of Research Neuropsychology Associates of Fairfax Assistant Professor of Neurology Georgetown University Medical Center
Multiple Sclerosis: An imaging review and update on new treatments.
Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter
Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller
Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller School of Medicine/University of Miami Question 1 You
Disease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
FastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
A Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.
Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the
Suicide Assessment in the Elderly Geriatric Psychiatric for the Primary Care Provider 2008
Suicide Assessment in the Elderly Geriatric Psychiatric for the Primary Care Provider 2008 Lisa M. Brown, Ph.D. Aging and Mental Health Louis de la Parte Florida Mental Health Institute University of South
Rational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València
Rational basis for early treatment in MS Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València Bonaventura Casanova Department of Neurology University Hospital La
Introduction to the DSM-IV and Psychological Testing
Introduction to the DSM-IV and Psychological Testing Significance of Mental Illness In any given year, how many Americans will suffer with a diagnosable mental illness? How many will suffer with a serious
MS an Mental Health. Alison Carolan MS Mental Health Nurse Kings College Hospital. IMPARTS December 2013
MS an Mental Health Alison Carolan MS Mental Health Nurse Kings College Hospital IMPARTS December 2013 MS and Mental Health MS is an autoimmune disease MS carries high risk of common mental disorders and
Cognitive Rehabilitation of Blast Traumatic Brain Injury
Cognitive Rehabilitation of Blast Traumatic Brain Injury Yelena Bogdanova, PhD VA Boston Healthcare System Rehabilitation Research & Development Boston University School of Medicine IOM Committee on Cognitive
Psychological and Neuropsychological Testing
2015 Level of Care Guidelines Psych & Neuropsych Testing Psychological and Neuropsychological Testing Introduction: The Psychological and Neuropsychological Testing Guidelines provide objective and evidencebased
DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
Advanced Multiple Sclerosis: Progressive MS Epidemiology
Advanced Multiple Sclerosis: Progressive MS Epidemiology CMSC 2007-Washington, DC Mitchell T. Wallin, MD, MPH Associate Director-Clinical Care VA MS Center of Excellence-East East Associate Professor of
ANXIETY & COGNITIVE IMPAIRMENT
ANXIETY & COGNITIVE IMPAIRMENT Dr. Sherri Hayden, Ph.D., R. Psych. Neuropsychologist, UBC Hospital Clinic for Alzheimer Disease & Related Disorders Clinical Assistant Professor, UBC Department of Medicine,
Neuropsychological Testing
Last Review Date: March 17, 2015 Number: MG.MM.ME.18dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
MRI in Differential Diagnosis
MRI in Differential Diagnosis Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC DISCLOSURES Speaking, consulting, and/or advisory boards
CBT IN THE CITY. adjusted to the news of being with MS? April 2013. Experts at your fingertips call now. Check out our new services in you local area
April 2013 Experts at your fingertips call now CBT IN THE CITY Check out our new services in you local area contents. A message from Susie, Information Multiple Sclerosis CBT can make a difference on the
Psychological and Neuropsychological Testing
Psychological and Neuropsychological Testing I. Policy University Health Alliance (UHA) will reimburse for Psychological and Neuropsychological Testing (PT/NPT) when it is determined to be medically necessary
Natalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
